Vaxcyte launches $500 million convertible senior notes offering due 2032
PCVX•Vaxcyte launched a $500 million offering of convertible senior notes due Oct. 15, 2032, with an underwriter option for up to $75 million more.
1. Offering details
The interest rate and initial conversion rate will be set at pricing. Vaxcyte plans to use the proceeds for VAX-31 clinical development, manufacturing scale-up, launch preparations, other research and development, and working capital.
